These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30378236)

  • 1. Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes.
    Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
    Diabetes Metab Res Rev; 2019 Feb; 35(2):e3093. PubMed ID: 30378236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus.
    Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
    Diabetologia; 2018 May; 61(5):1212-1219. PubMed ID: 29417184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.
    Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
    Am Heart J; 2014 May; 167(5):674-82.e1. PubMed ID: 24766977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.
    Kumar A; Patel DR; Wolski KE; Lincoff AM; Kashyap SR; Ruotolo G; McErlean E; Weerakkody G; Riesmeyer JS; Nicholls SJ; Nissen SE; Menon V
    Diab Vasc Dis Res; 2019 Mar; 16(2):171-177. PubMed ID: 31014095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Jagodzinski A; Havulinna AS; Appelbaum S; Zeller T; Jousilahti P; Skytte-Johanssen S; Hughes MF; Blankenberg S; Salomaa V
    Int J Cardiol; 2015 Aug; 192():33-9. PubMed ID: 25985013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 is an independent predictor of survival in systemic sclerosis.
    Faludi R; Nagy G; Tőkés-Füzesi M; Kovács K; Czirják L; Komócsi A
    Int J Cardiol; 2017 Apr; 233():118-124. PubMed ID: 28043664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography.
    Grübler MR; Delgado G; Kleber M; Hartaigh BÓ; de Boer RA; Verheyen N; Keppel M; Schmid J; Siontis GC; Räber L; Pieske B; Pilz S; Tomaschitz A; März W
    Am J Cardiol; 2020 Jul; 127():9-15. PubMed ID: 32418719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study.
    Vora A; de Lemos JA; Ayers C; Grodin JL; Lingvay I
    J Clin Endocrinol Metab; 2019 Oct; 104(10):4449-4458. PubMed ID: 31162551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study.
    Aguilar D; Sun C; Hoogeveen RC; Nambi V; Selvin E; Matsushita K; Saeed A; McEvoy JW; Shah AM; Solomon SD; Boerwinkle E; Ballantyne CM
    J Am Heart Assoc; 2020 Jul; 9(13):e015405. PubMed ID: 32573308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study.
    Liu S; Wu Q; Zhang S; Wang Z; Liu H; Teng L; Xiao P; Lu Y; Wang X; Dong C; Xiao J; Zhang J
    BMC Nephrol; 2022 Jan; 23(1):5. PubMed ID: 34979958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fibrosis marker galectin-3 and outcome in the general population.
    de Boer RA; van Veldhuisen DJ; Gansevoort RT; Muller Kobold AC; van Gilst WH; Hillege HL; Bakker SJ; van der Harst P
    J Intern Med; 2012 Jul; 272(1):55-64. PubMed ID: 22026577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies.
    Drechsler C; Delgado G; Wanner C; Blouin K; Pilz S; Tomaschitz A; Kleber ME; Dressel A; Willmes C; Krane V; Krämer BK; März W; Ritz E; van Gilst WH; van der Harst P; de Boer RA
    J Am Soc Nephrol; 2015 Sep; 26(9):2213-21. PubMed ID: 25568176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.
    Gellen B; Thorin-Trescases N; Thorin E; Gand E; Sosner P; Brishoual S; Rigalleau V; Montaigne D; Javaugue V; Pucheu Y; Gatault P; Piguel X; Hadjadj S; Saulnier PJ;
    Diabetologia; 2020 May; 63(5):915-923. PubMed ID: 32040670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.
    Tuegel C; Katz R; Alam M; Bhat Z; Bellovich K; de Boer I; Brosius F; Gadegbeku C; Gipson D; Hawkins J; Himmelfarb J; Ju W; Kestenbaum B; Kretzler M; Robinson-Cohen C; Steigerwalt S; Bansal N
    Am J Kidney Dis; 2018 Oct; 72(4):519-528. PubMed ID: 29866459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes.
    Sharif S; Van der Graaf Y; Cramer MJ; Kapelle LJ; de Borst GJ; Visseren FLJ; Westerink J;
    Cardiovasc Diabetol; 2021 Nov; 20(1):220. PubMed ID: 34753497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population.
    Hedbäck T; Almgren P; Nilsson PM; Melander O
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3437-44. PubMed ID: 27399347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.
    Ghorbani A; Bhambhani V; Christenson RH; Meijers WC; de Boer RA; Levy D; Larson MG; Ho JE
    J Am Coll Cardiol; 2018 Dec; 72(25):3246-3254. PubMed ID: 30573026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29).
    Drion I; Kleefstra N; Landman GW; Alkhalaf A; Struck J; Groenier KH; Bakker SJ; Bilo HJ
    Diabetes Care; 2012 Nov; 35(11):2354-8. PubMed ID: 22837372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serial galectin-3 and future cardiovascular disease in the general population.
    van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
    Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.